Prognostic role of HIST1H4C expression and neoadjuvant therapy efficacy in breast cancer

Purpose breast cancer is a common and highly malignant, currently, HIST1H4C was found to be associated with several human malignancies. The purpose of this study is to investigate tissue HIST1H4C expression in breast cancer and explore its role in disease progression and its interaction with neoadjuvant therapy efficacy. Methods we analyzed tissue HIST1H4C mRNA expression in BC tissue samples from 105 patients received with neoadjuvant therapy using qPCR between 2019–2022. Results Statistical analysis showed that a high expression of HIST1H4C before neoadjuvant therapy was positively related to good responder (CR + PR), while high expression of HIST1H4C after neoadjuvant therapy was negatively related good responder. And HIST1H4C expression was significantly decreased in patients with good responder. In addition, high HIST1H4C expression was also related to ER negative, PR negative, high KI67 expression, high level of histological grade, large tumor size and more lymph node metastases in Curtis database. Furthermore, high HIST1H4C expression before and after-treatment in our center or in database has a positively correlation with poor prognosis. Conclusions HIST1H4C is the potential biomarker of neoadjuvant therapy and prognosis for breast cancer.